Kaleido Biosciences Stock Debt To Equity
| KLDODelisted Stock | USD 0.01 0.00 0.00% |
Kaleido Biosciences fundamentals help investors to digest information that contributes to Kaleido Biosciences' financial success or failures. It also enables traders to predict the movement of Kaleido Pink Sheet. The fundamental analysis module provides a way to measure Kaleido Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kaleido Biosciences pink sheet.
Kaleido |
Kaleido Biosciences Company Debt To Equity Analysis
Kaleido Biosciences' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Kaleido Biosciences Debt To Equity | 2.04 % |
Most of Kaleido Biosciences' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kaleido Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Kaleido Biosciences has a Debt To Equity of 2.045%. This is 96.18% lower than that of the Pharmaceuticals sector and 89.44% lower than that of the Health Care industry. The debt to equity for all United States stocks is 95.8% higher than that of the company.
Kaleido Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kaleido Biosciences' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kaleido Biosciences could also be used in its relative valuation, which is a method of valuing Kaleido Biosciences by comparing valuation metrics of similar companies.Kaleido Biosciences is currently under evaluation in debt to equity category among its peers.
Kaleido Fundamentals
| Return On Equity | -5.81 | ||||
| Return On Asset | -1.0 | ||||
| Operating Margin | (79.28) % | ||||
| Current Valuation | (16.73 M) | ||||
| Shares Outstanding | 42.62 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 0.36 % | ||||
| Number Of Shares Shorted | 2.34 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 0 X | ||||
| Price To Sales | 0.04 X | ||||
| Revenue | 1.1 M | ||||
| Gross Profit | (66.7 M) | ||||
| EBITDA | (85.09 M) | ||||
| Net Income | (90.29 M) | ||||
| Cash And Equivalents | 38.47 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 5.55 M | ||||
| Debt To Equity | 2.04 % | ||||
| Current Ratio | 1.42 X | ||||
| Book Value Per Share | 0.25 X | ||||
| Cash Flow From Operations | (77.09 M) | ||||
| Short Ratio | 29.34 X | ||||
| Earnings Per Share | (2.16) X | ||||
| Target Price | 22.0 | ||||
| Number Of Employees | 76 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 421.96 K | ||||
| Total Asset | 50.14 M | ||||
| Retained Earnings | (197.63 M) | ||||
| Working Capital | 62.54 M | ||||
| Current Asset | 72.93 M | ||||
| Current Liabilities | 10.39 M | ||||
| Z Score | -6.3 | ||||
| Net Asset | 50.14 M |
About Kaleido Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kaleido Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kaleido Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kaleido Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Kaleido Pink Sheet
If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| CEOs Directory Screen CEOs from public companies around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |